百花医药或易主，自12月29日开市起停牌

Core Viewpoint - Baihua Pharmaceutical is planning a share transfer that may lead to a change in control of the company, with a trading suspension expected to last no more than two trading days starting December 29 [1]. Group 1: Shareholding Structure - The controlling shareholders, Mi Zaiqi, Mi Enhua, and Yang Xiaoling, are in the process of transferring shares, which may alter the company's control [1]. - As of December 1, 2025, the agreement among Mi Zaiqi, Mi Enhua, Yang Xiaoling, and their former joint action partner Li Jiancheng has been terminated, resulting in a change in the calculation of shareholding percentages [3]. - Mi Zaiqi, Mi Enhua, and Yang Xiaoling collectively hold 20.68% of Baihua Pharmaceutical, with individual holdings of 8.99%, 6.70%, and 4.99% respectively [4]. Group 2: Financial Performance - Baihua Pharmaceutical has experienced significant fluctuations in net profit from 2019 to 2024, with figures of 34.38 million, -320 million, 59.83 million, -34.76 million, 12.97 million, and 41.48 million yuan respectively [4]. - In the first three quarters of 2025, the net profit attributable to shareholders increased by 36.41% year-on-year, driven by improved project management and cost control [6]. - The company's total revenue for the current reporting period is approximately 965.20 million yuan, reflecting a year-on-year increase of 2.32% [6].